Mount Sinai Health System has partnered with a startup company to commercialize artificial intelligence solutions designed to improve kidney disease detection, management and treatment for patients with diabetes and other at-risk populations.
Under an exclusive multi-year license and collaboration agreement, Mount Sinai and RenalytixAI anticipate that the first product launch will occur in the second quarter of 2019.
The company’s AI technology will be deployed against Mount Sinai’s data warehouse containing more than 3 million patient health records and 43,000 patient records in a biobank repository, as well as de-identified clinical data, to create an advanced learning system to monitor and flag patients at risk for kidney disease.
“Our ability to apply the power of artificial intelligence against such a deep repository of clinical data in combination with prognostic biomarkers has the potential to change the game for all of our patients with diabetes and other populations at risk for kidney disease,” said Barbara Murphy, MD, dean for clinical integration and population health management and chair for the Department of Internal Medicine at the Icahn School of Medicine at Mount Sinai, as well as chair of the RenalytixAI Scientific Advisory Board.
According to Mount Sinai, about 1 million of its patients are either diagnosed with Type II diabetes or are of African ancestry—two of the major at-risk population segments for kidney disease. Other major U.S. healthcare systems are expected to participate in the clinical utility data development and product launch aimed at preventing dialysis and chronic kidney disease costs.
In 2018, RenalytixAI plans to pursue expanded clinical utility trials by collaborating with other academic medical centers, pharmaceutical companies and patient advocacy organizations in the U.S. and Europe, where kidney disease affects an estimated 12 percent or 120 million of the population, with 90 percent of patients unaware they are at risk. Ultimately, the startup intends to submit product applications for review by the Food and Drug Administration.
“This is a significant partnership for RenalytixAI with one of the largest hospital groups in the United States,” said RenalytixAI Executive Chairman Julian Baines. “The technology, alongside the Mount Sinai patient database, will improve patient care in end stage renal disease, a significant unmet medical need. The fact that so many patients on dialysis have never seen a specialist has to change, both from a patient care and cost perspective.”
Register or login for access to this item and much more
All Health Data Management content is archived after seven days.
Community members receive:
- All recent and archived articles
- Conference offers and updates
- A full menu of enewsletter options
- Web seminars, white papers, ebooks
Already have an account? Log In
Don't have an account? Register for Free Unlimited Access